EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Dementia with Lewy bodies and amyloid pathology: Eligible for anti‐amyloid treatment or not?

Lieza G Exalto iD, Juliette L van Alphen, Frederik Barkhof, Charlotte Teunissen, Everard G B Vijverberg, Dag Aarsland, Afina W Lemstra

Alzheimer's & Dementia · 2026-10 · 22 (10)

DOI: 10.1002/alz.71907 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia, online erschienen am 12.10.2026. Verfasst von Lieza G Exalto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer Center, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Lewy Body Disease, Alzheimer Disease, Amyloid beta-Peptides. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the future, treatment of dementia will be personalized, targeted to contributing pathologies, rather than the clinical syndrome. Anti‐amyloid drugs for Alzheimer's disease are the first approved drugs; however, the impact of co‑pathology on the treatment effects remains incomplete. Currently, only patients with a clinical diagnosis of Alzheimer's disease are eligible for these new drugs, but could they also be beneficial when amyloid is present in other neurodegenerative diseases? For example, roughly 50% of patients with dementia with Lewy bodies are amyloid‐positive. In this perspective, we discuss the theoretical benefits and challenges of anti‐amyloid drugs in patients with a clinical diagnosis of dementia with Lewy bodies and concomitant Alzheimer's disease pathology. We show that a significant portion of newly diagnosed dementia with Lewy bodies patients could be eligible. We advocate for the systematic collection of efficacy and safety data using innovative strategies to achieve adequate statistical power.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lewy Body DiseaseAlzheimer DiseaseAmyloid beta-PeptidesHumans

Stichwörter der Autor:innen

anti‐amyloid drugsappropriate use criteriadementia with Lewy bodies

Substanzen

Amyloid beta-Peptides

Autor:innen und Institutionen

  • Alzheimer Center, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Julius Clinical, Zeist, The Netherlands.
  • Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.
  • Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

ORCID-Profile: Lieza G Exalto

Zitieren

APA

Exalto, L. G., van Alphen, J. L., Barkhof, F., Teunissen, C., Vijverberg, E. G. B., Aarsland, D., & Lemstra, A. W. (2026). Dementia with Lewy bodies and amyloid pathology: Eligible for anti‐amyloid treatment or not?. Alzheimer's & Dementia, 22(10). https://doi.org/10.1002/alz.71907

Vancouver

Exalto LG, van Alphen JL, Barkhof F, Teunissen C, Vijverberg EGB, Aarsland D, et al. Dementia with Lewy bodies and amyloid pathology: Eligible for anti‐amyloid treatment or not?. Alzheimer's & Dementia. 2026;22(10). doi:10.1002/alz.71907

BibTeX
@article{Exalto2026,
  author = {Exalto, Lieza G and van Alphen, Juliette L and Barkhof, Frederik and Teunissen, Charlotte and Vijverberg, Everard G B and Aarsland, Dag and Lemstra, Afina W},
  title = {Dementia with Lewy bodies and amyloid pathology: Eligible for anti‐amyloid treatment or not?},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  volume = {22},
  number = {10},
  doi = {10.1002/alz.71907}
}
Kostenlos starten →